NCT01114542View on ClinicalTrials.gov

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 3, 2010

Primary Completion Date

August 10, 2010

Study Completion Date

August 10, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

DRUG

insulin glargine

Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY